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Abstract
Controlling protein interactions at the implanted electrode interface is becoming an important
strategy for the management of foreign body responses that have proven to be detrimental to the
long-term performance of neural prosthesis. In this study, PEGylation was conducted on
platinum bio-electrodes to render the surface protein-resistant. The PEGylated electrode was
investigated using a quartz crystal microbalance-dissipation, electrochemical impedance
spectroscopy and cyclic voltammetry.
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1. Introduction
The therapeutic efficacy of a chronically implanted neural prosthesis, such as the cochlear
implant, is determined by the ability to effectively transfer charge across the electrode-tissue
interface. A key factor is the host foreign body response that gives rise to fibrotic tissue
encapsulation of the neural probe, consequently insulating the electrode from targeted neurons.
Foreign body response typically arises from a biological cascade of non-desirable reactions, and
is triggered by non-specific protein adsorption at the device interface. Controlling the protein
interactions at the implanted electrode interface is thus becoming an important strategy for the
management of adverse tissue responses around the device.

PEGylation is orignially a pharmeceutical term, referring to covalent modification of
protein/peptide drugs with poly(ethylene glycol) derivatives (PEG, FDA-approved). There are
more than 8 PEGylated phamarceuticals receiving regulatory approval by the US and/or EU. 1
PEG is well-known for low toxicity and immunogenicity; it is highly soluble in water, and forms
a conformational cloud with high hydration numbers and polymer chain mobility, which is
responsible for excellent protein-resistant properties. 2 In addition to drug delivery, PEG has been
intensively explored as biocompatible, anti-fouling coatings for medical implants to improve the
in vivo efficacies. 3

The work reported here is a natural follow-up of our bioenginering effort involving the surface
modification of cochlear implants for enhanced electro-neural interfacing 4. PEGylation was
conducted on platinum electrodes to render the surface protein-resistant. The resultant PEG
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coating was investigated in terms of quartz crystal microbalance-dissipation (QCM-D),
electrochemical impedance spectroscopy (EIS) 5 and cyclic voltammetry (CV).

2. Experimental
2.1 Materials
mPEG thiols (Mw 5000 Da) were purchased from Jenkem Technology Co., Ltd, China.
Potassium hexacyanoferrate (III), potassium nitrate, bovine serum albumin (BSA) and fibrinogen
from bovine plasma were from Sigma-Aldrich, Australia. Pt electrodes (0.5 mm diameter),
similar size close to the electrode pad in cochlear implants, were custom-made from CH
Instrument, Inc., USA. Artificial perilymph solution (ARF, pH 7.4) was prepared to simulate the
body fluid in the cochlea, comprising NaCl (7.39 g/L), KHCO3 (0.35 g/L), NaHCO3 (2.02 g/L),
CaCl2 (0.08 g/L) and NH2C(CH2OH)3 (0.61 g/L).

Pt electrodes were polished using aqueous alumina slurry, and cleaned using cyclic voltammetry
in 0.5 M H2SO4 between -250 and 1200 mV (vs. an Ag│AgCl). The rinsed electrodes were
treated with a deoxygenated mPEG thiol solution in Milli-Q water (1.0 mM) overnight at room
temperature, rinsed and dried with N2 and denoted as Pt-PEG.

2.2 QCM-D measurements
QCM-D measurements were undertaken using a Q-Sense E4 system (Q-Sense AB, Sweden)
equipped with a multichannel peristaltic pump (IPC Ismatec SA, Switzerland). The QCM sensor
was an AT-cut quartz-crystal with a 10 mm diameter Pt electrode with a fundamental resonance
frequency of 5 MHz. For PEGylation, the Pt-coated sensor was equilibrated in Milli-Q water,
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followed by the introduction of mPEG thiol (1.0 mM in Milli-Q water) over 4 h, and then a rinse
with Milli-Q water until stabilised. For protein adsorption, both bare and PEGylated sensors
were equilibrated in ARF (for BSA) or 0.9 wt% NaCl (for fibrinogen), loaded with a BSA
solution in ARF (2.8 mg/mL) or a fibrinogen solution in 0.9 wt% NaCl (1.0 mg/mL) for 4 h, and
then rinsed with ARF (for BSA) or 0.9 wt% NaCl (for fibrinogen) until stabilised. The Voigt
model was selected to determine the hydrated layer mass (ng/cm2) and thickness of the PEG or
absorbed protein adlayers, using the 5th, 7th and 9th overtones. 6 The Q-tools software package
v.3.0.10.286 (Biolin Sci, AB) was used for data modelling, with the input parameters for the
layer density (1027 kg/m3), fluid density (1020 kg/m3), layer viscosity (10-5 ≤ 10-2 kg/ms), layer
shear modulus (104 ≤ 107 Pa), and mass (102 ≤ 105 ng/cm2).6

2.3 Electrochemical characterisation
A three-electrode electrochemical cell was used for all the electrochemical measurements,
consisting of a Pt or Pt-PEG working electrode, a platinum mesh auxiliary electrode and an
Ag│AgCl (3.0 M NaCl) reference electrode. EIS measurements were conducted on a Gamry EIS
3000TM, at open-circuit potential with AC amplitude of 10 mV. CV experiments were performed
using an EDAQ e-corder® electrochemical analysis system (EDAQ Pty Ltd, Australia).

3. Results and discussion
3.1 QCM-D
PEGylation of Pt electrode is realized via the formation of sulfur-platinum bonds 7. QCM-D was
employed to monitor the PEGylation process and protein adsorption behavior through changes in
resonance frequency (∆ƒ, coupled to layer hydrated mass) and energy dissipation (∆D, coupled
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to layer viscoelasticity). Injecting an mPEG thiol-containing solution onto a Pt-coated sensor
elicits an immediate decrease in frequency (Fig. 1A), suggesting a rise in the layer mass
attributable to the attached PEG and associated water, and the change in solute density above the
sensor. This is followed by a slow small rise in frequency attributed to mass loss arising from
dehydration of the resultant adlayer as a result of a further increased density of surface grafted
PEG 8. Rinsing the modified sensor with deionized water produces a further increase in frequency
until it reaches a plateau, as a result of the removal of any reversibly bound PEGs, as well as the
solute density change above the sensor.

The pronounced concurrent increase in dissipation upon PEGylation highlights the soft nature of
the water-rich PEG coating. The dissipation for the PEG adlayer reaches its maximum after ~30
minute exposure to the mPEG thiol. The PEG adlayer is deemed a viscoelastic hydrogel due to
the high degrees of hydration of PEG. 9,10 For instance, a number of studies reported on ≥ ~80
wt% water contents for surface-grafted PEGs. 11,12 By modeling the frequency and dissipation
shifts using the viscoelastic Voigt model, the thickness and mass of the hydrated PEG were
determined to be 8.0±0.4 nm and 822±46 ng/cm2, respectively.

Albumin and fibrinogen were selected for protein adsorption studies. Albumin is one of the most
abundant proteins in inner ear fluids 13; while fibrinogen is a serum protein, playing a critical role
in promoting inflammatory reactions to biomaterial implants 14. The time-resolved adsorption
kinetics of BSA and fibrinogen at a Pt electrode interface (Fig. 1B and C) illustrated the mass
uptake took place predominantly within the first 10-15 minute protein exposure. After a thorough
rinse to remove any weakly bound protein, the thickness and mass of the stabilized proteinaceous
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layers are 6.3±0.4 nm and 719±43 ng/cm2 for BSA, and 16.1±0.1 nm and 1855±1 ng/cm2 for
fibrinogen. The much higher uptake of fibrinogen, in comparison to BSA, is consistent with its
larger molecular size and increased hydrophobicity. Further insight into the Pt interface modified
either by the PEG or protein layer was obtained by examining the endpoint ∆D per respective
adlayer mass (∆m), ∆D/∆m. In comparison to that of the PEG layer, the endpoint ∆D/∆m value
decreases by a factor of 2.6 for the BSA layer, and by a factor of 3.0 for the fibrinogen layer
(Fig. 1D). This implies that the adsorbed BSA or fibrinogen on Pt surface constitute a much
stiffer layer, possibility with a lower water content. 15

The PEGylated Pt interface demonstrates excellent resistance to both BSA and fibrinogen
adsorption (Fig. 1B and C), with a typical endpoint ∆ƒ of <~2 for BSA uptake, and ~7.2 Hz for
fibrinogen uptake. When fitted using the Voigt model, these correspond to a mass below ~27
ng/cm2 for the absorbed BSA, and ~157 ng/cm2 for the absorbed fibrinogen, indicating ≥~92%
inhibition of protein adsorption at the electrode interface by PEGylation. However, these values
serve only as a rough estimation, given the difficulty to attain accurate mass for modeling such
small frequency changes.

3.2 Electrochemical characterization
Fig. 2A-D compares the CVs of bare and PEGylated Pt electrodes in 10 mM K3Fe(CN)6 before
and after protein adsorption. The bare electrode CV shows quasi-reversible oxidation and
reduction of the Fe(CN)63-/Fe(CN)64- at +285 and +150 mV, respectively (Fig. 2A). PEGylation
of the electrode surface results in a small decrease in the peak currents (e.g., ipcPt-PEG/ipcPt = 0.93)
and an increase in peak separation, reflecting an increased charge transfer resistance surface due
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to the presence of PEG layer. The shape of the CV then remains largely unchanged upon
exposure to BSA or fibrinogen (Fig. 2B). By contrast, the CV of the bare Pt electrode after
exposure to BSA or fibrinogen becomes plateau-shaped with a pronounced reduction in the
currents, emphasizing a strong blocking effect of the adsorbed proteinaceous layer (Fig. 2C). The
retained electron transfer capability of the PEGylated electrode surface in a protein-rich
environment as demonstrated in Fig. 2D, highlights the anti-fouling nature of the modified
electrode interface, which is in good agreement with our QCM-D results. It is worthwhile to
mention that the electrochemical behaviour of a redox probe chosen will depend on the chemical
interactions of both redox states with the electrode surface. 16,17 The use of ferri-ferrocyanide as a
redox probe in this study is justified as it allows comparison with a number of other studies that
use the same probe 18,19.

PEGylation of the Pt electrode produces a moderate increase in impedance over a broad
frequency range below ~104 Hz (Fig. 3A), and a negative shift in phase angle at 102–105 Hz (Fig.
3B). PEGylation also causes a small decrease in phase angle in the lower frequency region of
0.1-10 Hz. These characteristics are consistent with the presence of PEG at the electrode surface
that reduces both the double layer capacitance and electrode conductance. For instance,
PEGylation results in a decrease of ~54% at 1 kHz and ~40% at 10 kHz in double layer
capacitance, and a decrease of ~49% at 1 kHz and ~59% at 10 kHz in electrode conductance. For
cochlear implant electrodes, high-frequency impedance (≥ 1 kHz) is of importance as auditory
neural stimulation wherein biphasic current pulses with 25-100 µs pulse width can be
employed. 20 In this study, PEGylation elicits a more notable increase in the high-frequency
impedance than protein adsorption, e.g., an increase of ~90% in impedance at 1 kHz and ~30%
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at 10 kHz by PEGylation, as opposed to an increase of ~21% at 1 kHz and ~11% at 10 kHz by
fibrinogen adsorption (Fig. 3C). The PEGylated electrode shows negligible changes in
impedance after exposure to fibrinogen (Fig. 3D). Therefore it seems that the protein-resistant
property of the PEGylated electrode is achieved with compromised impedance. However, this
conclusion was drawn based on the result obtained in a much simplified in vitro condition. For
cochlear implants, the in-vivo impedance has shown to be governed predominantly by the
biological environment surrounding the electrode, such as fibrotic tissue response, and increase
up to 6-7 folds after a 12-week implantation. 21,22 The strategy of PEGylation reported here
provides some control over the evolution of the electrode-tissue interface by minimizing nonspecific protein adsorption and subsequent foreign body response. Since the nature of this
interface is critical to longer-term performance in-vivo studies are warranted in the future.

4. Conclusions
A simple method was developed for PEGylation of Pt bio-electrodes. The immobilized PEG
coating is highly hydrated and permeable, with a thickness of ~ 8 nm, and can inhibit ≥ ~92%
adsorption of both BSA and fibrinogen. Optimisation of the coating properties in terms of the invivo electrode performance is required in the future, and the knowledge gained will provide a
basis to facilitate the ongoing development of cochlear implants, as well as other types of neural
prostheses for improved electro-neural interfacing.
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Fig. 3. The IZI (A) and phase angle (B) plots of bare and PEGylated Pt electrodes; (C) comparison of the
impedance of Pt before and after fibrinogen adsorption (Pt + fibrinogen); (D) comparison of the
impedance of PEGylated Pt electrode before (Pt-PEG) and after fibrinogen adsorption (Pt-PEG +
fibrinogen). EIS was undertaken at open-circuit potential in air-purged ARF at room temperature, over
the frequency range of 0.1-100 kHz with AC amplitude of 10 mV. Protein adsorption procedure: Pt/PEGPt electrode was soaked in a fibrinogen solution (1.0 mg/mL) in 0.9 wt% NaCl for 2 h, and then rinsed
with deionized water and dried with N2.
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